文献速递胃肠动力与功能性疾病

低FODMAP饮食与传统饮食建议在餐后不适综合征中的随机临床试验

Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet vs Traditional Dietary Advice in Postprandial Functional Dyspepsia: A Randomized Clinical Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-15

这项英国单中心随机试验比较低FODMAP饮食与传统饮食建议对餐后不适综合征的疗效。共60例患者随机分组,低FODMAP饮食组在Leuven餐后不适量表评分临床显著降低(≥0.5分和≥0.7分)、症状充分缓解率及生活质量改善方面均优于传统饮食建议组。

要点

  • 低FODMAP饮食在餐后不适综合征的症状缓解上优于传统饮食建议。
  • 低FODMAP饮食组达到Leuven量表≥0.7分降低的比例显著更高。
  • 低FODMAP饮食组自报症状充分缓解率显著高于传统饮食建议组。

核心结论

  • 在餐后不适综合征患者中,低FODMAP饮食在症状缓解和生活质量改善方面优于传统饮食建议。

研究设计与样本

  • 英国单中心随机临床试验,共纳入60例餐后不适综合征患者,低FODMAP饮食组31例,传统饮食建议组29例。
  • 传统饮食建议包括少食多餐、减少咖啡因、酒精、碳酸饮料及高脂、加工或辛辣食物。
  • 主要终点为6周内Leuven餐后不适量表餐后不适综合征亚量表评分降低≥0.5分和≥0.7分的比例。

主要发现

  • Leuven餐后不适综合征亚量表降低≥0.5分者低FODMAP饮食组为61.3%,传统饮食建议组为37.9%(P = .04)。
  • 降低≥0.7分者低FODMAP饮食组为61.3%,传统饮食建议组为20.7%(P < .001)。
  • 低FODMAP饮食组在Leuven量表各症状、总体生活质量及总体胃肠道症状方面的改善均显著优于传统饮食建议组。
  • 自报消化不良症状充分缓解(第4-6周≥50%时间)者低FODMAP饮食组为71.0%,传统饮食建议组为34.5%(P = .005)。

关键数值与推荐

  • 主要终点采用Leuven餐后不适量表餐后不适综合征亚量表评分降低≥0.5分和≥0.7分。
  • 症状充分缓解定义为第4-6周期间≥50%时间自报消化不良症状充分缓解。

临床怎么用

  • 对于餐后不适综合征患者,可考虑将低FODMAP饮食作为饮食管理选择之一。
  • 传统饮食建议(少食多餐、减少咖啡因/酒精/碳酸饮料/高脂/加工/辛辣食物)仍可作为基础饮食指导。

局限性

  • 本研究为单中心随机试验,样本量较小(共60例)。
  • 研究人群以女性(78%)、白人(78%)为主,且63%合并肠易激综合征,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Postprandial distress syndrome affects 80% of individuals with functional dyspepsia, yet evidence-based dietary management strategies remain poorly defined. This United Kingdom-based, single-center, randomized trial compared traditional dietary advice with a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet in postprandial distress syndrome. METHODS: Participants with postprandial distress syndrome received dietary education on traditional dietary advice (ie, small, frequent meals with reduction of caffeine, alcohol, carbonated beverages, and high-fat, processed, or spicy foods) or a low FODMAP diet. Questionnaires were completed at baseline and over 6 weeks, including the Leuven Postprandial Distress Scale, which was used to determine the primary endpoint of clinically meaningful reductions in the postprandial distress syndrome subscale of the Leuven Postprandial Distress Scale (≥0.5 points and ≥0.7 points). Secondary endpoints included individual changes to the Leuven Postprandial Distress Scale, changes in the overall Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index for quality of life, and self-reported adequate relief of dyspeptic symptoms (≥50% of the time during weeks 4-6). RESULTS: A total of 60 patients with postprandial distress syndrome underwent randomization; 31 were assigned to the low FODMAP diet and 29 to the traditional dietary advice group. Baseline characteristics were similar between groups, with mean age 39.6 years, 78% female, 78% white, and coexistent irritable bowel syndrome in 63%. For the primary endpoint, a ≥0.5-point reduction in postprandial distress syndrome subscale was achieved by 61.3% with the low FODMAP diet vs 37.9% with traditional dietary advice (P = .04), while a ≥0.7-point reduction was achieved by 61.3% with the low FODMAP diet vs 20.7% with traditional dietary advice (P < .001). The low FODMAP diet group demonstrated significantly greater improvements in individual Leuven Postprandial Distress Scale symptoms, overall quality of life, and overall gastrointestinal symptoms compared with traditional dietary advice. Adequate relief of dyspepsia was self-reported by 71.0% with the low FODMAP diet vs 34.5% with traditional dietary advice (P = .005). CONCLUSIONS: A low FODMAP diet was superior to traditional dietary advice for achieving symptom relief and quality of life improvement in postprandial distress syndrome. CLINICALTRIALS: gov, Number: NCT05810168.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shiha MG, Buckle RL, Shaw CC, et al. Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet vs Traditional Dietary Advice in Postprandial Functional Dyspepsia: A Randomized Clinical Trial. Clin Gastroenterol Hepatol. 2026. PMID: 42297316. doi:10.1016/j.cgh.2026.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。